Q-omics provides the consensus-scored ZNF486 profile across patient tissues and cancer cell-line models. ZNF486 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF486 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, ZNF486 RNA expression shows 19,515 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where ZNF486 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF486 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF486 survival associations across molecular data types. ZNF486 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF486 RNA expression–survival associations across cancer types. High ZNF486 expression shows unfavorable associations in LGG, but favorable associations in KIRC, LUAD, HNSC, GBM and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF486 RNA expression.
This table summarizes ZNF486 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF486. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF486 shows lower tumor expression in KICH, UCEC, LUSC and READ and higher tumor expression in BRCA and LIHC. The KICH box plot shows higher ZNF486 RNA expression in normal versus tumor tissue (log2 FC = −1.831, t-test p < 0.001).
This table shows molecular features associated with ZNF486 in patient tissues and cancer cell lines. In patient samples, ZNF486 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF486 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
